GLP-1 receptor agonist therapy was associated with lower all-cause mortality among people with hidradenitis suppurativa — a benefit that lasted up to 2 years, according to a study published in JAMA Dermatology.These findings were consistent even among patients without diabetes who had HS, according to Beata Jastrząb-Miśkiewicz, MD, PhD, a dermatologist, venereologist and lead investigator of the study.“It suggests that…
Source: Healio News
